Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic.
Identifieur interne : 000F73 ( Main/Exploration ); précédent : 000F72; suivant : 000F74Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic.
Auteurs : M. Kasperkiewicz [États-Unis] ; E. Schmidt [Allemagne] ; J A Fairley [États-Unis] ; P. Joly [France] ; A S Payne [États-Unis] ; M L Yale [États-Unis] ; D. Zillikens [Allemagne] ; D T Woodley [États-Unis]Source :
- Journal of the European Academy of Dermatology and Venereology : JEADV [ 1468-3083 ] ; 2020.
Descripteurs français
- KwdFr :
- Betacoronavirus (isolement et purification), Cloque (complications), Cloque (traitement médicamenteux), Facteurs immunologiques (usage thérapeutique), Guides de bonnes pratiques cliniques comme sujet (MeSH), Hormones corticosurrénaliennes (usage thérapeutique), Humains (MeSH), Infections à coronavirus (complications), Infections à coronavirus (virologie), Infections à coronavirus (épidémiologie), Maladies auto-immunes (complications), Maladies auto-immunes (traitement médicamenteux), Pandémies (MeSH), Pneumopathie virale (complications), Pneumopathie virale (virologie), Pneumopathie virale (épidémiologie).
- MESH :
- isolement et purification : Betacoronavirus.
- traitement médicamenteux : Cloque, Maladies auto-immunes.
- usage thérapeutique : Cloque, Facteurs immunologiques, Hormones corticosurrénaliennes, Infections à coronavirus, Maladies auto-immunes, Pneumopathie virale.
- virologie : Infections à coronavirus, Pneumopathie virale.
- épidémiologie : Infections à coronavirus, Pneumopathie virale.
- Guides de bonnes pratiques cliniques comme sujet, Humains, Pandémies.
English descriptors
- KwdEn :
- Adrenal Cortex Hormones (therapeutic use), Autoimmune Diseases (complications), Autoimmune Diseases (drug therapy), Betacoronavirus (isolation & purification), Blister (complications), Blister (drug therapy), Coronavirus Infections (complications), Coronavirus Infections (epidemiology), Coronavirus Infections (virology), Humans (MeSH), Immunologic Factors (therapeutic use), Pandemics (MeSH), Pneumonia, Viral (complications), Pneumonia, Viral (epidemiology), Pneumonia, Viral (virology), Practice Guidelines as Topic (MeSH).
- MESH :
- chemical , therapeutic use : Adrenal Cortex Hormones, Immunologic Factors.
- complications : Autoimmune Diseases, Blister, Coronavirus Infections, Pneumonia, Viral.
- drug therapy : Autoimmune Diseases, Blister.
- epidemiology : Coronavirus Infections, Pneumonia, Viral.
- isolation & purification : Betacoronavirus.
- virology : Coronavirus Infections, Pneumonia, Viral.
- Humans, Pandemics, Practice Guidelines as Topic.
DOI: 10.1111/jdv.16525
PubMed: 32333823
PubMed Central: PMC7267551
Affiliations:
- Allemagne, France, États-Unis
- Californie, Haute-Normandie, Iowa, Pennsylvanie, Région Normandie
- Iowa City, Los Angeles, Rouen
- Université de Californie du Sud, Université de l'Iowa
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic.</title><author><name sortKey="Kasperkiewicz, M" sort="Kasperkiewicz, M" uniqKey="Kasperkiewicz M" first="M" last="Kasperkiewicz">M. Kasperkiewicz</name><affiliation wicri:level="4"><nlm:affiliation>Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region><settlement type="city">Los Angeles</settlement></placeName><orgName type="university">Université de Californie du Sud</orgName></affiliation></author><author><name sortKey="Schmidt, E" sort="Schmidt, E" uniqKey="Schmidt E" first="E" last="Schmidt">E. Schmidt</name><affiliation wicri:level="1"><nlm:affiliation>Department of Dermatology, University of Lübeck, Lübeck, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Dermatology, University of Lübeck, Lübeck</wicri:regionArea><wicri:noRegion>Lübeck</wicri:noRegion><wicri:noRegion>Lübeck</wicri:noRegion><wicri:noRegion>Lübeck</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Lübeck Institute of Experimental Dermatology (LIED), University of Lübeck, Lübeck, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Lübeck Institute of Experimental Dermatology (LIED), University of Lübeck, Lübeck</wicri:regionArea><wicri:noRegion>Lübeck</wicri:noRegion><wicri:noRegion>Lübeck</wicri:noRegion><wicri:noRegion>Lübeck</wicri:noRegion></affiliation></author><author><name sortKey="Fairley, J A" sort="Fairley, J A" uniqKey="Fairley J" first="J A" last="Fairley">J A Fairley</name><affiliation wicri:level="4"><nlm:affiliation>Department of Dermatology, University of Iowa, Iowa City, IA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Dermatology, University of Iowa, Iowa City, IA</wicri:regionArea><placeName><region type="state">Iowa</region><settlement type="city">Iowa City</settlement></placeName><orgName type="university">Université de l'Iowa</orgName></affiliation></author><author><name sortKey="Joly, P" sort="Joly, P" uniqKey="Joly P" first="P" last="Joly">P. Joly</name><affiliation wicri:level="3"><nlm:affiliation>Department of Dermatology, Rouen University Hospital, Rouen, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Dermatology, Rouen University Hospital, Rouen</wicri:regionArea><placeName><region type="region">Région Normandie</region><region type="old region">Haute-Normandie</region><settlement type="city">Rouen</settlement></placeName></affiliation></author><author><name sortKey="Payne, A S" sort="Payne, A S" uniqKey="Payne A" first="A S" last="Payne">A S Payne</name><affiliation wicri:level="2"><nlm:affiliation>Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Dermatology, University of Pennsylvania, Philadelphia, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Yale, M L" sort="Yale, M L" uniqKey="Yale M" first="M L" last="Yale">M L Yale</name><affiliation wicri:level="2"><nlm:affiliation>International Pemphigus and Pemphigoid Foundation, Sacramento, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>International Pemphigus and Pemphigoid Foundation, Sacramento, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Zillikens, D" sort="Zillikens, D" uniqKey="Zillikens D" first="D" last="Zillikens">D. Zillikens</name><affiliation wicri:level="1"><nlm:affiliation>Department of Dermatology, University of Lübeck, Lübeck, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Dermatology, University of Lübeck, Lübeck</wicri:regionArea><wicri:noRegion>Lübeck</wicri:noRegion><wicri:noRegion>Lübeck</wicri:noRegion><wicri:noRegion>Lübeck</wicri:noRegion></affiliation></author><author><name sortKey="Woodley, D T" sort="Woodley, D T" uniqKey="Woodley D" first="D T" last="Woodley">D T Woodley</name><affiliation wicri:level="4"><nlm:affiliation>Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region><settlement type="city">Los Angeles</settlement></placeName><orgName type="university">Université de Californie du Sud</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32333823</idno><idno type="pmid">32333823</idno><idno type="doi">10.1111/jdv.16525</idno><idno type="pmc">PMC7267551</idno><idno type="wicri:Area/Main/Corpus">001598</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001598</idno><idno type="wicri:Area/Main/Curation">001598</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001598</idno><idno type="wicri:Area/Main/Exploration">001598</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic.</title><author><name sortKey="Kasperkiewicz, M" sort="Kasperkiewicz, M" uniqKey="Kasperkiewicz M" first="M" last="Kasperkiewicz">M. Kasperkiewicz</name><affiliation wicri:level="4"><nlm:affiliation>Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region><settlement type="city">Los Angeles</settlement></placeName><orgName type="university">Université de Californie du Sud</orgName></affiliation></author><author><name sortKey="Schmidt, E" sort="Schmidt, E" uniqKey="Schmidt E" first="E" last="Schmidt">E. Schmidt</name><affiliation wicri:level="1"><nlm:affiliation>Department of Dermatology, University of Lübeck, Lübeck, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Dermatology, University of Lübeck, Lübeck</wicri:regionArea><wicri:noRegion>Lübeck</wicri:noRegion><wicri:noRegion>Lübeck</wicri:noRegion><wicri:noRegion>Lübeck</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Lübeck Institute of Experimental Dermatology (LIED), University of Lübeck, Lübeck, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Lübeck Institute of Experimental Dermatology (LIED), University of Lübeck, Lübeck</wicri:regionArea><wicri:noRegion>Lübeck</wicri:noRegion><wicri:noRegion>Lübeck</wicri:noRegion><wicri:noRegion>Lübeck</wicri:noRegion></affiliation></author><author><name sortKey="Fairley, J A" sort="Fairley, J A" uniqKey="Fairley J" first="J A" last="Fairley">J A Fairley</name><affiliation wicri:level="4"><nlm:affiliation>Department of Dermatology, University of Iowa, Iowa City, IA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Dermatology, University of Iowa, Iowa City, IA</wicri:regionArea><placeName><region type="state">Iowa</region><settlement type="city">Iowa City</settlement></placeName><orgName type="university">Université de l'Iowa</orgName></affiliation></author><author><name sortKey="Joly, P" sort="Joly, P" uniqKey="Joly P" first="P" last="Joly">P. Joly</name><affiliation wicri:level="3"><nlm:affiliation>Department of Dermatology, Rouen University Hospital, Rouen, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Dermatology, Rouen University Hospital, Rouen</wicri:regionArea><placeName><region type="region">Région Normandie</region><region type="old region">Haute-Normandie</region><settlement type="city">Rouen</settlement></placeName></affiliation></author><author><name sortKey="Payne, A S" sort="Payne, A S" uniqKey="Payne A" first="A S" last="Payne">A S Payne</name><affiliation wicri:level="2"><nlm:affiliation>Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Dermatology, University of Pennsylvania, Philadelphia, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Yale, M L" sort="Yale, M L" uniqKey="Yale M" first="M L" last="Yale">M L Yale</name><affiliation wicri:level="2"><nlm:affiliation>International Pemphigus and Pemphigoid Foundation, Sacramento, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>International Pemphigus and Pemphigoid Foundation, Sacramento, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Zillikens, D" sort="Zillikens, D" uniqKey="Zillikens D" first="D" last="Zillikens">D. Zillikens</name><affiliation wicri:level="1"><nlm:affiliation>Department of Dermatology, University of Lübeck, Lübeck, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Dermatology, University of Lübeck, Lübeck</wicri:regionArea><wicri:noRegion>Lübeck</wicri:noRegion><wicri:noRegion>Lübeck</wicri:noRegion><wicri:noRegion>Lübeck</wicri:noRegion></affiliation></author><author><name sortKey="Woodley, D T" sort="Woodley, D T" uniqKey="Woodley D" first="D T" last="Woodley">D T Woodley</name><affiliation wicri:level="4"><nlm:affiliation>Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region><settlement type="city">Los Angeles</settlement></placeName><orgName type="university">Université de Californie du Sud</orgName></affiliation></author></analytic><series><title level="j">Journal of the European Academy of Dermatology and Venereology : JEADV</title><idno type="eISSN">1468-3083</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adrenal Cortex Hormones (therapeutic use)</term><term>Autoimmune Diseases (complications)</term><term>Autoimmune Diseases (drug therapy)</term><term>Betacoronavirus (isolation & purification)</term><term>Blister (complications)</term><term>Blister (drug therapy)</term><term>Coronavirus Infections (complications)</term><term>Coronavirus Infections (epidemiology)</term><term>Coronavirus Infections (virology)</term><term>Humans (MeSH)</term><term>Immunologic Factors (therapeutic use)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (complications)</term><term>Pneumonia, Viral (epidemiology)</term><term>Pneumonia, Viral (virology)</term><term>Practice Guidelines as Topic (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Betacoronavirus (isolement et purification)</term><term>Cloque (complications)</term><term>Cloque (traitement médicamenteux)</term><term>Facteurs immunologiques (usage thérapeutique)</term><term>Guides de bonnes pratiques cliniques comme sujet (MeSH)</term><term>Hormones corticosurrénaliennes (usage thérapeutique)</term><term>Humains (MeSH)</term><term>Infections à coronavirus (complications)</term><term>Infections à coronavirus (virologie)</term><term>Infections à coronavirus (épidémiologie)</term><term>Maladies auto-immunes (complications)</term><term>Maladies auto-immunes (traitement médicamenteux)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (complications)</term><term>Pneumopathie virale (virologie)</term><term>Pneumopathie virale (épidémiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adrenal Cortex Hormones</term><term>Immunologic Factors</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Autoimmune Diseases</term><term>Blister</term><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Autoimmune Diseases</term><term>Blister</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Cloque</term><term>Maladies auto-immunes</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Cloque</term><term>Facteurs immunologiques</term><term>Hormones corticosurrénaliennes</term><term>Infections à coronavirus</term><term>Maladies auto-immunes</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Pandemics</term><term>Practice Guidelines as Topic</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Guides de bonnes pratiques cliniques comme sujet</term><term>Humains</term><term>Pandémies</term></keywords></textClass></profileDesc></teiHeader></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32333823</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>31</Day></DateCompleted><DateRevised><Year>2020</Year><Month>07</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-3083</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>7</Issue><PubDate><Year>2020</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of the European Academy of Dermatology and Venereology : JEADV</Title><ISOAbbreviation>J Eur Acad Dermatol Venereol</ISOAbbreviation></Journal><ArticleTitle>Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic.</ArticleTitle><Pagination><MedlinePgn>e302-e303</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/jdv.16525</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kasperkiewicz</LastName><ForeName>M</ForeName><Initials>M</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-0146-1661</Identifier><AffiliationInfo><Affiliation>Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Dermatology, University of Lübeck, Lübeck, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lübeck Institute of Experimental Dermatology (LIED), University of Lübeck, Lübeck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fairley</LastName><ForeName>J A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Dermatology, University of Iowa, Iowa City, IA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joly</LastName><ForeName>P</ForeName><Initials>P</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-5734-0255</Identifier><AffiliationInfo><Affiliation>Department of Dermatology, Rouen University Hospital, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Payne</LastName><ForeName>A S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yale</LastName><ForeName>M L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>International Pemphigus and Pemphigoid Foundation, Sacramento, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zillikens</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Dermatology, University of Lübeck, Lübeck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woodley</LastName><ForeName>D T</ForeName><Initials>DT</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Eur Acad Dermatol Venereol</MedlineTA><NlmUniqueID>9216037</NlmUniqueID><ISSNLinking>0926-9959</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000305">Adrenal Cortex Hormones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000305" MajorTopicYN="N">Adrenal Cortex Hormones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001327" MajorTopicYN="N">Autoimmune Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001768" MajorTopicYN="N">Blister</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="Y">Practice Guidelines as Topic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>04</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>04</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32333823</ArticleId><ArticleId IdType="doi">10.1111/jdv.16525</ArticleId><ArticleId IdType="pmc">PMC7267551</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Schmidt E, Kasperkiewicz M, Joly P. Pemphigus. Lancet 2019; 394: 882-894.</Citation></Reference><Reference><Citation>Schmidt E, Zillikens D. Pemphigoid diseases. Lancet 2013; 381: 320-332.</Citation></Reference><Reference><Citation>Russell B, Moss C, George G et al. Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence. Ecancermedicalscience 2020; 14: 1022.</Citation></Reference><Reference><Citation>Wollenberg A, Flohr C, Simon D et al. European Task Force on Atopic Dermatitis (ETFAD) statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2)-infection and atopic dermatitis. J Eur Acad Dermatol Venereol 2020. https://doi.org/10.1111/jdv.16411</Citation></Reference><Reference><Citation>Joly P, Maho-Vaillant M, Prost-Squarcioni C et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet 2017; 389: 2031-2040.</Citation></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li><li>France</li><li>États-Unis</li></country><region><li>Californie</li><li>Haute-Normandie</li><li>Iowa</li><li>Pennsylvanie</li><li>Région Normandie</li></region><settlement><li>Iowa City</li><li>Los Angeles</li><li>Rouen</li></settlement><orgName><li>Université de Californie du Sud</li><li>Université de l'Iowa</li></orgName></list><tree><country name="États-Unis"><region name="Californie"><name sortKey="Kasperkiewicz, M" sort="Kasperkiewicz, M" uniqKey="Kasperkiewicz M" first="M" last="Kasperkiewicz">M. Kasperkiewicz</name></region><name sortKey="Fairley, J A" sort="Fairley, J A" uniqKey="Fairley J" first="J A" last="Fairley">J A Fairley</name><name sortKey="Payne, A S" sort="Payne, A S" uniqKey="Payne A" first="A S" last="Payne">A S Payne</name><name sortKey="Woodley, D T" sort="Woodley, D T" uniqKey="Woodley D" first="D T" last="Woodley">D T Woodley</name><name sortKey="Yale, M L" sort="Yale, M L" uniqKey="Yale M" first="M L" last="Yale">M L Yale</name></country><country name="Allemagne"><noRegion><name sortKey="Schmidt, E" sort="Schmidt, E" uniqKey="Schmidt E" first="E" last="Schmidt">E. Schmidt</name></noRegion><name sortKey="Schmidt, E" sort="Schmidt, E" uniqKey="Schmidt E" first="E" last="Schmidt">E. Schmidt</name><name sortKey="Zillikens, D" sort="Zillikens, D" uniqKey="Zillikens D" first="D" last="Zillikens">D. Zillikens</name></country><country name="France"><region name="Région Normandie"><name sortKey="Joly, P" sort="Joly, P" uniqKey="Joly P" first="P" last="Joly">P. Joly</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F73 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000F73 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32333823
|texte= Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32333823" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidFranceV1
| This area was generated with Dilib version V0.6.37. |  |